| scholarly article | Q13442814 |
| P2093 | author name string | R Kohli | |
| O Pankewycz | |||
| N Sridhar | |||
| N Leca | |||
| J Karam | |||
| R Venuto | |||
| I Min | |||
| A Gundroo | |||
| G Blessios | |||
| M Laftavi | |||
| P2860 | cites work | Children with septo-optic dysplasia - how to improve and sharpen the diagnosis | Q30602450 |
| Increased risk of fracture in patients receiving solid organ transplants | Q33535343 | ||
| Mechanism of transplantation-associated bone loss | Q33982249 | ||
| Involution of the parathyroid glands after renal transplantation | Q35157947 | ||
| Mechanisms of glucocorticoid-induced osteoporosis | Q35159553 | ||
| Four gland parathyroidectomy without reimplantation in patients with chronic renal failure | Q35521695 | ||
| Bone disease after kidney transplantation | Q35632536 | ||
| Cinacalcet hydrochloride | Q35999571 | ||
| Glucocorticoids act directly on osteoblasts and osteocytes to induce their apoptosis and reduce bone formation and strength | Q40604863 | ||
| Natural history of parathyroid function and calcium metabolism after kidney transplantation: a single-centre study | Q44782158 | ||
| Percutaneous penetration of topically applied melatonin in a cream and an alcoholic solution | Q44982442 | ||
| A prospective randomized study for the treatment of bone loss with vitamin d during kidney transplantation in children and adolescents | Q45171036 | ||
| Successful treatment of hypercalcemia with cinacalcet in renal transplant recipients with persistent hyperparathyroidism | Q46533192 | ||
| The calcimimetic cinacalcet normalizes serum calcium in renal transplant patients with persistent hyperparathyroidism | Q46533193 | ||
| Secondary hyperparathyroidism is associated with vitamin D receptor polymorphism and bone density after renal transplantation. | Q46637844 | ||
| Parathyroidectomy for parathyroid carcinoma in renal transplantation. | Q53274570 | ||
| P433 | issue | 10 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | hyperparathyroidism | Q1344835 |
| P304 | page(s) | 2391-2395 | |
| P577 | publication date | 2006-07-26 | |
| P1433 | published in | American Journal of Transplantation | Q4744273 |
| P1476 | title | Early and severe hyperparathyroidism associated with hypercalcemia after renal transplant treated with cinacalcet. | |
| P478 | volume | 6 |
| Q36995930 | Abnormal bone and mineral metabolism in kidney transplant patients--a review. |
| Q35463999 | CKD-MBD after kidney transplantation |
| Q43284029 | Calcimimetics and bone mineral density in renal transplant patients with persistent secondary hyperparathyroidism |
| Q37182739 | Calcimimetics in chronic kidney disease: evidence, opportunities and challenges |
| Q37123164 | Calcium metabolism in the early posttransplantation period. |
| Q46587079 | Cinacalcet for hypercalcaemic secondary hyperparathyroidism after renal transplantation: a multicentre, retrospective, 3-year study |
| Q39728456 | Clinical impact of hypercalcemia in kidney transplant |
| Q92470356 | Effect of Cinacalcet in Kidney Transplant Patients With Hyperparathyroidism |
| Q51909974 | Elevated calcium phosphate product after renal transplantation is a risk factor for graft failure. |
| Q42910524 | Evaluation of Cinacalcet HCl Treatment After Kidney Transplantation |
| Q52715921 | Extreme hypercalcemia in a kidney transplant recipient. |
| Q35226929 | Long-term clinical practice experience with cinacalcet for treatment of hypercalcemic hyperparathyroidism after kidney transplantation |
| Q34405366 | Measuring total blood calcium displays a low sensitivity for the diagnosis of hypercalcemia in incident renal transplant recipients. |
| Q38452732 | Mineral and bone disorders in kidney transplant recipients: reversible, irreversible, and de novo abnormalities |
| Q55509850 | Myelofibrosis-Induced Erythropoietin-Resistant Anemia Due to Severe Refractory Hyperparathyroidism. |
| Q37111857 | New strategies for the treatment of hyperparathyroidism incorporating calcimimetics |
| Q34589090 | Pharmacokinetics and pharmacodynamics of cinacalcet in patients with hyperparathyroidism after renal transplantation |
| Q38594874 | Phosphate and FGF-23 homeostasis after kidney transplantation |
| Q35573650 | Potential future uses of calcimimetics in patients with chronic kidney disease |
| Q37820101 | Renal allograft failure in a hyperparathyroid patient following initiation of a calcimimetic |
| Q39225566 | Retrospective Study Looking at Cinacalcet in the Management of Hyperparathyroidism after Kidney Transplantation |
| Q39314892 | Systematic review of surgical and medical treatment for tertiary hyperparathyroidism |
| Q34626324 | The effect of cinacalcet on intraoperative findings in tertiary hyperparathyroidism patients undergoing parathyroidectomy |
| Q88122810 | The effect of hypercalcemia on allograft calcification after kidney transplantation |
| Q33597429 | The effects of discontinuing cinacalcet at the time of kidney transplantation |
| Q37013105 | The role of calcimimetics in the treatment of hyperparathyroidism |
| Q37767247 | Therapeutic management of post-kidney transplant hyperparathyroidism |
| Q42776198 | Treatment of hyperparathyroidism with cinacalcet in kidney transplant recipients |
| Q37715190 | Treatment with calcimimetics in kidney transplantation |
| Q34984752 | Vitamin D and cinacalcet administration pre-transplantation predict hypercalcaemic hyperparathyroidism post-transplantation: a case-control study of 355 deceased-donor renal transplant recipients over 3 years |
Search more.